Baobab AiBio (바오밥에이바이오)
Incheon, South Korea
The KRAS mutation is an oncogene that is common in all human cancers, and it is known that the incidence of mutation is high in major cancers such as pancreatic cancer, colon cancer, and lung cancer. Due to its clinical importance, KRAS inhibitor drug development has been attempted for over 30 years, but there is no cure yet. In addition, Familial Adenomatous Polyposis (FAP), which is caused by APC mutations, is a rare hereditary disease in which numerous polyps occur in the colon from 10 to 20 years old. In order to provide a new breakthrough in the treatment of such intractable and rare diseases, Baobab A Bio Co. , Ltd. uses artificial intelligence platform technology and is striving to develop new drugs targeting innovative targets.
Only accessible to MedStartr community members.
Join nowCompany Info
- Founded
- 2018
- Website
- www.baobabaibio.com/
Categories
Disease Areas
Technologies
Only accessible to MedStartr community members.
Join nowWhat do you think of Baobab AiBio (바오밥에이바이오)?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.
Only accessible to MedStartr community members.
Join now